AIM ImmunoTech, Inc.

AIM ImmunoTech Inc. is focused on developing innovative solutions. The company is engaged in various studies to demonstrate the efficacy of its lead product.

NYSEAMERICAN: AIM
IR Website: aimimmuno.com
Headquarters: Ocala, FL
Investor Contact: aim@jtcir.com

TALK TO MANAGEMENT

AIM ImmunoTech Inc. is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.

Summary

Investor Presentation

CEO Corner Videos & Virtual Investor Series

Strong Cash Position & Poised for Commercialization

Management Overview

printing_white

Thomas K. Equels, M.S. J.D.
Chief Executive Officer

Thomas K. Equels is AIM ImmunoTech's Chief Executive Officer (since 2016), President (since 2015), and Executive Vice Chairman (since 2008). He has also been a Director since 2008. Mr. Equels was formerly President and Managing Director of the Equels Law Firm in Miami, Fla., representing various sectors in complex matters. He began his professional career as a military pilot, serving in Vietnam, and received multiple honors. He holds degrees from Florida State University and Troy University. In 2012, he was Knighted by Pope Benedict.

David R. Strayer, MD
Medical Officer

Dr. David R. Strayer is AIM ImmunoTech's Chief Scientific & Medical Officer, appointed in February 2016, and has served as Medical Director since 1986. He is recognized as a leading expert. Dr. Strayer has held academic positions and is Board Certified. He has led significant research studies and received his MD from the University of California at Los Angeles in 1972.

Peter W. Rodino III, JD
Chief Operating Officer, Executive Director for Governmental Relations, General Counsel, Secretary

Peter W. Rodino III has been a Director since July 2013. On October 1, 2016, he transitioned to serve as Executive Director for Governmental Relations and General Counsel, later becoming Chief Operating Officer on October 16, 2019. Mr. Rodino has extensive legal, financial, and executive experience, having served as President of Rodino Consulting LLC and in leadership roles at several law firms. He holds a B.S. in Business Administration from Georgetown University and a J.D. from Seton Hall University.

Robert Dickey IV
Chief Financial Officer

Robert Dickey IV has been AIM ImmunoTech's Chief Financial Officer since April 4, 2022. He has over 25 years of financial leadership experience in life science and device companies, both private and public. Mr. Dickey has held senior roles at Foresite Advisors and Danforth Advisors, providing financial support and investment advisory services. He served on the boards of Emmaus Life Sciences and Sanuthera, Inc., and was CFO of Motif Plc. Mr. Dickey has an MBA from The Wharton School and an AB from Princeton University.

Christopher McAleer, PhD
Scientific Officer

Christopher McAleer, Ph.D., joined AIM ImmunoTech in June 2022 and was promoted to Scientific Officer in December 2022. Before joining AIM ImmunoTech, Dr. McAleer worked at Hesperos, Inc., where he contributed to the company's growth. His role included leading various research projects. Dr. McAleer holds degrees in Biology and Chemistry from West Chester University of Pennsylvania, a Master's in Molecular Biology and Microbiology, and a Doctorate in Biomedical Sciences from the University of Central Florida, where he also completed his postdoctoral research.

Risks & Disclosures

printing_white

This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.

AIM ImmunoTech Inc. (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.

Information and opinions presented in the Company Presentation are provided by the Company, and makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.

Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.

A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.

Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.

b2i digital or its related entities may own securities of the Company.

The Company is a client of b2i Digital. The Company agreed to pay b2i Digital no greater than $100,000 in cash for 12 months of digital marketing consulting and investor awareness services.

This communication includes forward-looking statements that involve risks, uncertainties and assumptions that are difficult to predict. Words and expressions reflecting optimism, satisfaction or disappointment with current prospects, as well as words such as “believes,” “hopes,” “intends,” “estimates,” “expects,” “projects,” “plans,” “anticipates” and variations thereof, or the use of future tense, identify forward-looking statements, but their absence does not mean that a statement is not forward-looking. The Company’s forward-looking statements are not guarantees of performance, and actual results could vary materially from those contained in or expressed by such statements due to risks, uncertainties and other factors. The Company urges readers to consider specifically the various risk factors identified in its most recent Form 10-K, and any risk factors or cautionary statements included in any subsequent Form 10-Q or Form 8-K, filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this communion. Except as required by law, the Company does not undertake any responsibility to update any forward-looking statements to take into account events or circumstances that occur after the date of this communication.

Management Team

THOMAS K EQUELS, M.S., J.D.

Thomas K Equels, M.S., J.D.

Thomas K Equels, M.S., J.D.
Chief Executive Officer, President & Executive Vice Chairman

THOMAS K. EQUELS, M.S., J.D. has been the Chief Executive Officer of AIM ImmunoTech Inc. since February 2016. Additionally, he has served as a Director on the company’s Board of Directors since 2008. Mr. Equels previously served as the company’s Secretary from 2008 to 2016, its General Counsel from 2010 to 2016, and its Chief Financial Officer from December 2013 to February 2016. Mr. Equels was formerly the President and Managing Director of the Equels Law Firm in Miami, Fla. For over a quarter century, he represented national governments, state governments and private companies in banking, insurance, aviation, pharmaceutical and construction matters. He also was on numerous occasions the court-appointed receiver to turn around distressed companies. Mr. Equels received his Juris Doctor degree with high honors from Florida State University. He is a summa cum laude graduate with a Bachelor of Science from Troy University. He also has a Master of Science from Troy University. He is a member of the Florida Bar Association and the American Bar Association.

PETER W. RODINO III, J.D.

Peter W. Rodino III, J.D.

Peter W. Rodino III, J.D.
Chief Operating Officer, Executive Director for Governmental Relations, General Counsel, Secretary

PETER W. RODINO, III, J.D., was named Executive Director for Governmental Relations and General Counsel in October 2016 and Secretary in November 2016. Mr. Rodino was appointed a Director of the Company in July 2013 and served in that capacity until his resignation to permit him to serve the company in this new capacity. While on the Board, he served as Lead Director, Chairman and Financial Expert of the Audit Committee; as a member of the Compensation Committee; and as a member of the Governance and Nomination Committee. Mr. Rodino has broad legal, financial and executive experience. In addition to being President of Rodino Consulting LLC and managing partner at several law firms during his many years as a practicing attorney, he served as Chairman and CEO of Crossroads Health Plan, the first major Health Maintenance Organization in New Jersey. He also has experience as an investment executive in the securities industry and acted as trustee in numerous Chapter 11 complex corporate reorganizations. Mr. Rodino holds a Juris Doctor degree from Seton Hall University and a Bachelor of Science in Business Administration from Georgetown University.

DAVID R. STRAYER, M.D.

David R. Strayer, M.D.

David R. Strayer, M.D.
Medical Officer

Dr. Strayer has acted as Medical Director since 1986 and was appointed Medical Officer in 2016. He is a former Professor of Medicine and Neoplastic Diseases at Hahnemann University. Dr. Strayer is Board Certified in Medical Oncology and Internal Medicine with research interests in the fields of cancer and immune system disorders. He has served as principal investigator in studies funded by the Leukemia Society of America, the American Cancer Society, and the National Institutes of Health. Dr. Strayer attended the School of Medicine at the University of California at Los Angeles where he received his M.D. in 1972.

ROBERT DICKEY IV, MBA

Robert Dickey IV, MBA

Robert Dickey IV, MBA
Chief Financial Officer

ROBERT DICKEY IV has more than 25 years of experience of C-suite financial leadership for life science and medical device companies, both private and public, ranging from preclinical development to commercial operations and across a variety of disease areas and medical technologies.

CHRISTOPHER MCALEER, PH.D.

Christopher McAleer, Ph.D.

Christopher McAleer, Ph.D.
Scientific Officer

Dr. McAleer has acted as Scientific Officer since his appointment in December 2022. Prior to joining the Company in June 2022 as Deputy Scientific Officer, he held positions at Hesperos, Inc., where he helped to build a start-up biotech CRO from a 3-employee $500K/year operation to a 30 person $5+ million/year operation. In his most recent role at Hesperos as Principal Scientist Dr. McAleer was responsible for leading teams in higher throughput operations projects as well as prototype projects including both NIH-funded and industry-sponsored which included studies of neuromuscular disorders, human complement pathways, cardiac dysfunction, liver metabolism and PKPD modeling, M/NAFLD, sarcopenia, and metabolic syndrome, and autoimmune diseases. Prior to his appointment as Principal Scientist, he served as Senior Scientist from 2016-2019 where he led a team to build a multi-organ MPS-based model using human and rat primary and iPSC derived tissues to study interspecies differences of drug toxicity. Additionally, as Senior Scientist he was responsible for writing in full or in part 7 funded NIH SBIR grant proposals as well as executing 4 contracts for private client partners resulting in repeat business from all 4 clients totaling ~$1.3 million. Additionally, Dr. McAleer has authored published manuscripts in several peer-reviewed science and nature journals, book chapters and scientific conference publications. His manuscript titled “Multi-organ system for the evaluation of efficacy and off-target toxicity of anticancer therapeutics,” published in Science Translational Medicine in December 2019 had the distinction of being featured by then-NIH director Francis Collins’ weekly blog.

Dr. McAleer received his Bachelor of Science Education in Biology and Chemistry degrees from West Chester University of Pennsylvania, and his Masters in Molecular Biology and Microbiology as well as his Doctorate in Biomedical Sciences from University of Central Florida. He completed his post-doctoral research at the University of Central Florida.

AIM ImmunoTech, Inc. is led by a team of dedicated professionals with extensive expertise.

The AIM ImmunoTech, Inc. team regularly updates investors with their company's news. Please fill out this form to receive the latest information.

Note: The company can only disclose information that is shared in the public domain through press releases, SEC filings, and other public forums. As securities law and industry regulations require, such information will always be shared with all investors simultaneously.